Molecular Pharmacology and Physiology

David Morgan J-5989-2012

David Morgan, Ph.D.

Distinguished Professor, College of Medicine Psychiatry and Behavioral Neurosciences

Ceo / Director, Byrd Alzheimer Institute

Distinguished Professor, Tcop Dept of Pharmaceutical Science

Contact Info Alzheimer Institute
4001 E. Fletcher Ave
Tampa FL 33613

Academic Email:

Academic Phone:(813) 974-3949

View My C.V.


  • PHD, Neurobiology, Northwestern University, 1981
  • M.S., Neurobiology, Northwestern University, 1978
  • B.A., Philosophy/Psychology, Northwestern University, 1974

Academic Philosophy

"When exploring the truly unknown, one must proceed blindly. New knowledge is a process of random variation and selective retention."

Interdisciplinary and Emerging Signature Programs

  • Allergy, Immunology & Infectious Disease
  • Biomedical Engineering & Nanomedicine
  • Metabolic Regulation and Disorders
  • Neurodegenerative Disease
  • Neuroscience

Research Interests

  • Fundamental changes in aging brain and age related neurological disorders
  • Role of astrocytes and microglial cells in the brains reaction to injury .
  • Development of animal models for age-related neurodegenerative disorders, such as Alzheimer's and Parkinson's disease
  • Identification of the mechanisms leading to neuron loss in neurodegenerative disorders.
  • Testing of therapeutic agents addressing the mechanisms of neurotoxicity in age-related neurodegenerative disorders


  • ASNTR (Councilor, 1998 - Present)
  • Society for Neuroscience (member, 1980 - Present)
  • Researchers Against Alzheimer's (Lead Representative, 2012 - Present)

Recent Publications

  • Schroeder S, Joly-Amado A, Soliman A, Sengupta U, Kayed R, Gordon MN, Morgan D. Oligomeric tau-targeted immunotherapy in Tg4510 mice. Alzheimer's research & therapy. 9(1) : 46, 2017.
  • He M Singh P Cheng S Zhang Q Peng W Ding X Li L Liu J Premont RT Morgan D Burns JM Swerdlow RH Suo WZ. GRK5 Deficiency Leads to Selective Basal Forebrain Cholinergic Neuronal Vulnerability. Sci Rep.. 6: 26116, 2016.
  • Schroeder SK Joly-Amado A Gordon MN Morgan D. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies. J Neuroimmune Pharmacol. 11(1) : 9-25, 2016.
  • Selenica MB Reid P Pena G Alvarez J Hunt JB Jr Nash KR Morgan D Gordon MN Lee DC. Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking. J Immunol Methods. 432: 51-56, 2016.
  • Lister JJ Harrison Bush AL Andel R Matthews C Morgan D Edwards JD. Cortical auditory evoked responses of older adults with and without probable mild cognitive impairment. Clin Neurophysiol. 127(2) : 1279-87, 2016.
  • Breydo L Morgan D Uversky VN. Pseudocatalytic Antiaggregation Activity of Antibodies: Immunoglobulins can Influence α-Synuclein Aggregation at Substoichiometric Concentrations. Mol Neurobiol.. 53(3) : 1949-58, 2016.
  • Hunt JB Jr Nash KR Placides D Moran P Selenica ML Abuqalbeen F Ratnasamy K Slouha N Rodriguez-Ospina S Savlia M Ranaweera Y Reid P Dickey CA Uricia R Yang CG Sandusky LA Gordon MN Morgan D Lee DC. Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy. J Neurosci. 35(44) : 14842-60, 2015.
  • Cheng J Lin X Morgan D Gordon M Chen X Wang ZH Li HN He LJ Zhou SF Cao C. Dendritic and Langerhans cells respond to Aβ peptides differently: implication for AD immunotherapy. Oncotarget.. 6(34) : 35443-57, 2015.
  • Heneka MT Carson MJ El Khoury J Landreth GE Brosseron F Feinstein DL Jacobs AH Wyss-Coray T Vitorica J Ransohoff RM Herrup K Frautschy SA Finsen B Brown GC Verkhratsky A Yamanaka K Koistinaho J Latz E Halle A Petzold GC Town TMorgan D Shinohara ML Perry VH Holmes C Bazan NG Brooks DJ Hunot S Joseph B Deigendesch N Garaschuk O Boddeke E Dinarello CA Breitner JC Cole GM Golenbock DT Kummer MP. Neuroinflammation in Alzheimer's disease. Lancet Neurol.. 14: 388-405, 2015.
  • Delic V Brownlow M Joly-Amado A Zivkovic S Noble K Phan TA Ta Y Zhang Y Bell SD Kurien C Reynes C Morgan D Bradshaw PC. Calorie restriction does not restore brain mitochondrial function in P301L tau mice, but it does decrease mitochondrial F0F1-ATPase activity. Mol Cell Neurosci.. 67: 46-54, 2015.
  • Woo JA Boggess T Uhlar C Wang X Khan H Cappos G Joly-Amado A De Narvaez E Majid S Minamide LS Bamburg JR Morgan D Weeber E Kang D. RanBP9 at the intersection between cofilin and Aβ pathologies: rescue of neurodegenerative changes by RanBP9 reduction. Cell Death. 6: 1676, 2015.
  • Woo JA Zhao X Khan H Penn C Wang X Joly-Amado A Weeber E Morgan D Kang D. Slingshot-Cofilin activation mediates mitochondrial and synaptic dysfunction via Aβ ligation to β1-integrin conformers. Cell Death Differ.. 6: 921-24, 2015.
  • Nash KR Moran P Finneran D Hudson C Robinson J Morgan D Bickford PC. Fractalkine Over Expression Suppresses α-Synuclein mediated Neurodegeneration. Mol Ther.. , 2014.
  • Fargo KN Aisen P Albert M Au R Corrada MM DeKosky S Drachman D Fillit H Gitlin L Haas M Herrup K Kawas C Khachaturian AS Khachaturian ZS Klunk W Knopman D Kukull WA Lamb B Logsdon RG Maruff P Mesulam M Mobley W Mohs R Morgan D Nixon RA Paul S Petersen R Plassman B Potter W Reiman E Reisberg B Sano M Schindler R Schneider LS Snyder PJ Sperling RA Yaffe K Bain LJ Thies WH Carrillo MC. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimers Dement.. 10(5) : S430-52, 2014.
  • Selenica ML Davtyan H Housley SB Blair LJ Gillies A Nordhues BA Zhang B Liu J Gestwicki JE Lee DC Gordon MN Morgan D Dickey CA. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation. 11: 152, 2014.
  • Haghighi M Smith A Morgan D Small B Huang S. Identifying Cost-Effective Predictive Rules of Amyloid-β Level by Integrating Neuropsychological Tests and Plasma- Based Markers. J Alzheimers Dis.. 43: 1261-70, 2014.
  • Joly-Amado A Brownlow M Pierce J Ravipati A Showalter E Li Q Gordon MN Morgan D. Intraventricular human immunoglobulin distributes extensively but fails to modify amyloid in a mouse model of amyloid deposition. Curr. Alzheimer Res.. 11(7) : 664-671, 2014.
  • Brownlow ML Joly-Amado A Azam S Elza M Selenica ML Pappas C Small B Engelman R Gordon MN Morgan D. Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. Behav. Brain Res.. 271: 79-88, 2014.
  • Quiroga C Chaparro RE Karlnoski R Erasso D Gordon M Morgan D Bosco G Rubini A Parmagnani A Paoli A Mangar D Camporesi EM. Effects of Repetitive Exposure to Anesthetics and Analgesics in the Tg2576 Mouse Alzheimer's Model. Neurotox. Res.. 6(1) : 414-21, 2014.
  • Selenica ML Benner L Housley SB Manchec B Lee DC Nash KR Kalin J Bergman JA Kozikowski A Gordon MN Morgan D. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alz. Res & Ther.. 6(1) : 12, 2014.
  • Lee DC, Ruiz CR, Lebson L, Selenica ML, Rizer J, Hunt JB, Rojiani R, Reid P, Kammath S, Nash K, Dickey CA, Gordon M, Morgan D. Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiology of aging. 34(6) : 1610-20, 2013.
  • Carty N, Nash KR, Brownlow M, Cruite D, Wilcock D, Selenica ML, Lee DC, Gordon MN, Morgan D. Intracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PloS one. 8(3) : e59626, 2013.
  • Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, Reid P, Mouton PR, Morgan D, Gordon MN. Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. Journal of neuroinflammation. 10: 86, 2013.
  • Brownlow ML, Benner L, D'Agostino D, Gordon MN, Morgan D. Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. PloS one. 8(9) : e75713, 2013.
  • Selenica ML, Brownlow M, Jimenez JP, Lee DC, Pena G, Dickey CA, Gordon MN, Morgan D. Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neuro-degenerative diseases. 11(4) : 165-81, 2013.
  • Nash KR, Lee DC, Hunt JB, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, Gemma C, Bickford PC, Gordon MN, Morgan D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiology of aging. 34(6) : 1540-8, 2013.
  • Lee DC, Rizer J, Hunt JB, Selenica ML, Gordon MN, Morgan D. Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathology and applied neurobiology. 39(1) : 69-85, 2013.
  • Zhu Y, Obregon D, Hou H, Giunta B, Ehrhart J, Fernandez F, Mori T, Nikolic W, Zhao Y, Morgan D, Town T, Tan J. Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. Journal of cellular and molecular medicine. 15(2) : 327-38, 2011.
  • Morgan D. Immunotherapy for Alzheimer's disease. Journal of internal medicine. 269(1) : 54-63, 2011.
  • Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE, Gordon MN, Morgan D, Nash K. Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of neuroscience methods. 194(1) : 144-53, 2010.
  • Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. Journal of neuroinflammation. 7: 56, 2010.
  • Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, Li Q, Szekeres K, Jinwal U, Koren J, Dickey CA, Gottschall PE, Morgan D, Gordon MN. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 30(29) : 9651-8, 2010.
  • Ajmo JM, Bailey LA, Howell MD, Cortez LK, Pennypacker KR, Mehta HN, Morgan D, Gordon MN, Gottschall PE. Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw. Journal of neurochemistry. 113(3) : 784-95, 2010.
  • Li QY, Gordon MN, Chackerian B, Alamed J, Ugen KE, Morgan D. Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 5(1) : 133-42, 2010.
  • Jinwal UK, Miyata Y, Koren J, Jones JR, Trotter JH, Chang L, O'Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ER, Gestwicki JE, Dickey CA. Chemical manipulation of hsp70 ATPase activity regulates tau stability. The Journal of neuroscience : the official journal of the Society for Neuroscience. 29(39) : 12079-88, 2009.
  • Morgan D. The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS & neurological disorders drug targets. 8(1) : 7-15, 2009.
  • Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Pettersson FE, Nilsson LN. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. The FEBS journal. 276(4) : 995-1006, 2009.
  • Morgan D, Landreth G, Bickford P. The promise and perils of an Alzheimer disease vaccine: a video debate. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 4(1) : 1-3, 2009.
  • Karlnoski RA, Rosenthal A, Kobayashi D, Pons J, Alamed J, Mercer M, Li Q, Gordon MN, Gottschall PE, Morgan D. Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 29(15) : 4964-71, 2009.
  • Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee D, Dickson D, de Silva R, Binder LI, Morgan D, Lewis J. Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. The American journal of pathology. 174(1) : 228-38, 2009.
  • Carty NC, Nash K, Lee D, Mercer M, Gottschall PE, Meyers C, Muzyczka N, Gordon MN, Morgan D. Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces Abeta Deposits in APP + PS1 Transgenic Mice. Molecular therapy : the journal of the American Society of Gene Therapy. , 2008.
  • Morgan D, Munireddy S, Alamed J, DeLeon J, Diamond DM, Bickford P, Hutton M, Lewis J, McGowan E, Gordon MN. Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. Journal of Alzheimer's disease : JAD. 15(4) : 605-14, 2008.
  • Li Q, Gordon M, Etienne MA, Hammer RP, Morgan D. Contrasting in vivo effects of two peptide-based amyloid-beta protein aggregation inhibitors in a transgenic mouse model of amyloid deposition. Cell transplantation. 17(4) : 397-408, 2008.
  • Karlnoski RA, Rosenthal A, Alamed J, Ronan V, Gordon MN, Gottschall PE, Grimm J, Pons J, Morgan D. Deglycosylated Anti-Abeta Antibody Dose-Response Effects on Pathology and Memory in APP Transgenic Mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. , 2008.
  • Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks B, Sun M, Cheng JQ, Patterson C, Bailey RM, Dunmore J, Soresh S, Leon C, Morgan D, Petrucelli L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proceedings of the National Academy of Sciences of the United States of America. 105(9) : 3622-7, 2008.
  • Morgan D, Gordon MN. Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. (2008). Behavioral neuroscience. 122(3) : 730-2, 2008.
  • Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, Morgan D, Gordon MN. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2(2) : 222-31, 2007.
  • Li Q, Gordon M, Cao C, Ugen KE, Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC neuroscience. 8: 22, 2007.
  • Morgan D. Amyloid, memory and neurogenesis. Experimental neurology. 205(2) : 330-5, 2007.
  • Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, Ehrhart J, Shytle RD, Giunta B, Morgan D, Town T, Tan J. Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proceedings of the National Academy of Sciences of the United States of America. 104(7) : 2507-12, 2007.
  • Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience. 144(3) : 950-60, 2007.
  • Karlnoski R, Wilcock D, Dickey C, Ronan V, Gordon MN, Zhang W, Morgan D, Taglialatela G. Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiology of disease. 25(1) : 179-88, 2007.
  • Herber DL, Maloney JL, Roth LM, Freeman MJ, Morgan D, Gordon MN. Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia. 53(4) : 382-91, 2006.
  • Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D. Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of neuroinflammation. 3: 11, 2006.
  • Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nature protocols. 1(3) : 1591-5, 2006.
  • Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 26(20) : 5340-6, 2006.
  • Morgan D. Immunotherapy for Alzheimer's disease. Journal of Alzheimer's disease : JAD. 9(3 Suppl) : 425-32, 2006.
  • Morgan D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochemistry international. 49(2) : 190-4, 2006.
  • Morgan D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neuro-degenerative diseases. 2(5) : 261-6, 2005.
  • Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 25(38) : 8807-14, 2005.
  • Dickey CA, Gordon MN, Wilcock DM, Herber DL, Freeman MJ, Morgan D. Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC neuroscience. 6(1) : 7, 2005.
  • Morgan D, Gordon MN, Tan J, Wilcock D, Rojiani AM. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. Journal of neuropathology and experimental neurology. 64(9) : 743-53, 2005.
  • Townsend KP, Town T, Mori T, Lue LF, Shytle D, Sanberg PR, Morgan D, Fernandez F, Flavell RA, Tan J. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. European journal of immunology. 35(3) : 901-10, 2005.
  • Garcia MF, Gordon MN, Hutton M, Lewis J, McGowan E, Dickey CA, Morgan D, Arendash GW. The retinal degeneration (rd) gene seriously impairs spatial cognitive performance in normal and Alzheimer's transgenic mice. Neuroreport. 15(1) : 73-7, 2004.
  • Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiology of disease. 15(1) : 11-20, 2004.
  • Dickey CA, Gordon MN, Mason JE, Wilson NJ, Diamond DM, Guzowski JF, Morgan D. Amyloid suppresses induction of genes critical for memory consolidation in APP + PS1 transgenic mice. Journal of neurochemistry. 88(2) : 434-42, 2004.
  • Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. The Journal of neuroscience : the official journal of the Society for Neuroscience. 24(27) : 6144-51, 2004.
  • Dickey CA, De Mesquita DD, Morgan D, Pennypacker KR. Induction of memory-associated immediate early genes by nerve growth factor in rat primary cortical neurons and differentiated mouse Neuro2A cells. Neuroscience letters. 366(1) : 10-4, 2004.
  • Townsend KP, Shytle DR, Bai Y, San N, Zeng J, Freeman M, Mori T, Fernandez F, Morgan D, Sanberg P, Tan J. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. Journal of neuroscience research. 78(2) : 167-76, 2004.
  • Herber DL, Severance EG, Cuevas J, Morgan D, Gordon MN. Biochemical and histochemical evidence of nonspecific binding of alpha7nAChR antibodies to mouse brain tissue. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 52(10) : 1367-76, 2004.
  • Herber DL, Roth LM, Wilson D, Wilson N, Mason JE, Morgan D, Gordon MN. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Experimental neurology. 190(1) : 245-53, 2004.
  • Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Journal of neuroinflammation. 1(1) : 24, 2004.
  • Morgan D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochemical research. 28(7) : 1029-34, 2003.
  • Austin L, Arendash GW, Gordon MN, Diamond DM, DiCarlo G, Dickey C, Ugen K, Morgan D. Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. Behavioral neuroscience. 117(3) : 478-84, 2003.
  • Kassed CA, Butler TL, Navidomskis MT, Gordon MN, Morgan D, Pennypacker KR. Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-kappaB p50 in hippocampal neurons after injury. Brain research. Molecular brain research. 110(1) : 152-7, 2003.
  • Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(12) : 5219-26, 2003.
  • Morgan D. Antibody therapy for Alzheimer's disease. Expert review of vaccines. 2(1) : 53-9, 2003.
  • Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 23(9) : 3745-51, 2003.
  • Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Experimental neurology. 173(2) : 183-95, 2002.
  • Morgan D, Keller RK. What evidence would prove the amyloid hypothesis? Towards rational drug treatments for Alzheimer's disease. Journal of Alzheimer's disease : JAD. 4(3) : 257-60, 2002.
  • Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. 22(6) : 2246-54, 2002.
  • Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain research. 891(1-2) : 42-53, 2001.
  • Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KV, Hope CE, Hatcher JM, DiCarlo G, Gottschall WP, Morgan D, Arendash GW. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiology of aging. 22(3) : 377-85, 2001.
  • Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815) : 982-5, 2000.
  • Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature medicine. 4(1) : 97-100, 1998.
  • Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383(6602) : 710-3, 1996.


  • Medical Hero Award (Temple Terrace Chamber of Commerce - 2012)
  • Distinguished Health Professor (University of South Florida - 2010)
  • USF President's Award for Faculty Excellence (University of South Florida - 2002)
  • Established Investigator Award (American Heart Association - 1989)